Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Extension of Therapeutic Indications for Enzalutamide

New indication concerns the treatment of adult men with high-risk non-metastatic CRPC
25 Sep 2018
Genitourinary cancers;  Anticancer agents & Biologic therapy

On 20 September 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product enzalutamide (Xtandi). 

The marketing authorisation holder for this medicinal product is Astellas Pharma Europe B.V.

 The CHMP adopted a new indication as follows: treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). 

For information, the full indications for Xtandi will be as follows

Xtandi is indicated for: 

  • the treatment of adult men with high-risk non-metastatic CRPC. 
  • the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. 
  • the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 25 Sep 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.